Know Cancer

forgot password

A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab

Phase 1/Phase 2
18 Years
Not Enrolling
Metastatic Breast Cancer

Thank you

Trial Information

A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab

Inclusion Criteria:

The following criteria are to be checked at the time of study entry. The patients may only
be included in the study if ALL of the following statements are FULLFILLED:

1. The patient (male or female) is at least 18 years old at the time of signature of the
informed consent form.

2. Written informed consent has been obtained from the patient prior to the performance
of any protocol-specific procedure.

3. The patient is diagnosed with confirmed invasive breast cancer with stage IV disease.

Note: If the metastatic disease is restricted to a solitary lesion, its neoplastic
nature should be confirmed by cytology or histology.

4. The patient has documented disease progression or relapse following at least one
prior standard therapy with trastuzumab (alone or in combination with chemotherapy).

Patients with prior lapatinib use are eligible. Furthermore,

- The administration of the chemotherapeutic agent(s) should have been stopped for
at least 28 days by the time of the first ASCI administration.

- The administration of trastuzumab alone could be maintained after chemotherapy,
but the last dose of trastuzumab should not have been given less than three
weeks before the first ASCI administration.

- The patient will not be given trastuzumab during the trial.

5. For metastatic patients whose disease is ER+ and/or PR+ the following criteria should
be met:

- Patients with visceral disease that requires chemotherapy (eg., patients with
liver or lung metastases).

- Rapidly progressing or life threatening disease, as determined by the

- Patients who received hormonal therapy and are no longer benefiting from this

6. A tumor lesion from the patient biopsied before or during screening shows either:

- Overexpression of the HER2 protein, as determined by immunohistochemistry (IHC,
with result IHC 3+) or

- Amplification of the HER2 gene as determined by FISH (at least 4 fold i.e. at
least 8 copies).

Note: Overexpression/amplification measurements must be performed on a metastatic
lesion in all cases where such a lesion is sufficiently easily accessible. If however
such a biopsy is not possible, then these measurements can be performed on the
primary tumor. Use of the primary tumor is to be documented and justified.

Ten FFPE tissue sections of the tumor on which the HER2 overexpression/amplification
has been done -if available-may be requested. These may be used to retrospectively
carry out part of the translational research (i.e. analysis of EGF receptor activity
and of the presence of immune effector cells, refer to Section 7).

7. The patient has at least one measurable lesion according to RECIST criteria.

8. The patient has ECOG status of 0 or 1.

9. The patient has adequate bone marrow reserve as indicated by:

- White blood cell count >/= 3,000/mm3.

- Neutrophil count >/= 1,500/mm3.

- Platelet count >/= 100,000/mm3.

- Hemoglobin levels >/= 10.0 g/dl.

10. The patient has adequate renal function as shown by the creatinine levels (i.e.
within the normal range).

11. The patient has adequate hepatic function as shown by serum bilirubin levels i.e:

- Serum bilirubin levels within the normal limits.

- Both AST and ALT levels <1.5 times the ULN. Note: However, for patients with
liver metastasis, a serum bilirubin level <1.5 times the ULN and both AST and
ALT levels <3 times the ULN will be accepted.

12. The patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA
scan equal to or greater than the LLN for the radiology facility.

13. If the patient is female, she must be of non-childbearing potential, i.e. have a
current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is
of childbearing potential, she must practice adequate contraception for 30 days prior
to treatment, have a negative pregnancy test and continue such precautions for two
months after completion of the study treatment.

Adequate contraception is defined as a contraceptive method with failure rate of less
than 1% per year when used consistently and correctly (when applicable, as mentioned
in the product label) for example abstinence, combined or progestogen oral
contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic
vaginal ring, percutaneous contraceptive patches or intrauterine device (IUD) or
intrauterine system (IUS), vasectomy with documented azoospermia of the sole male
partner or double barrier method (condom or occlusive cap plus spermicidal agent).

For azoospermia, "documented" refers to the outcome of the investigator's/ designee's
medical examination of the subject or review of the subject's medical history for
study eligibility, as obtained via a verbal interview with the subject or from the
subject's medical records.

Post-menopause: Menopause is the age associated with complete cessation of menstrual
cycles, menses, and implies the loss of reproductive potential by ovarian failure. A
practical definition accepts menopause after 1 year without menses with an
appropriate clinical profile at the appropriate age e.g. > 45 years.

14. Able to swallow and retain oral medication.

15. In the view of the investigator, the patient can and will comply with the
requirements of the protocol.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If any apply, the
patient must not be included in the study:

1. The patient has received > 300 mg/m2 doxorubicin (cumulative dose) or > 600 mg/m2
epirubicin (cumulative dose).

2. The patient is receiving treatment with bisphosphonate UNLESS the biphosphonate
treatment was initiated more than three weeks before the first ASCI administration.
(See also section 5.3.2.).

3. The patient has received any investigational or non-registered product (drug or
vaccine) other than the study treatment(s) within 30 days preceding the first dose of
study treatment, or planned use during the study period.

4. The patient is currently receiving amiodarone or has received amiodarone in the 6
months prior to screening.

5. The patient requires concomitant treatment with systemic corticosteroids or any
immunosuppressive agents. The use of prednisone, or equivalent, <0.5 mg/kg/day
(absolute maximum 40 mg/day), or inhaled corticosteroids or topical steroids is

6. The patient has a malabsorption syndrome, disease significantly affecting
gastrointestinal function, or resection of the stomach or small bowel.

7. Patients with ulcerative colitis.

8. The patient has known coronary artery disease, arrhythmia requiring treatment,
clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular
hypertrophy (found by ECG) or previous myocardial infarction.

9. The patient has any acute or chronic, clinically significant pulmonary,
cardiovascular, hepatic or renal functional abnormality, as determined by physical
examination or laboratory screening tests.

10. The patient has current active hepatic or biliary's disease (with exception of
patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable
chronic liver disease per investigator assessment).

11. The patient presents with autoimmune disease (vitiligo and autoimmune thyroid disease
is not an exclusion criterion).

12. The patient has a known family history of congenital or hereditary immunodeficiency.

13. The patient has any uncontrolled bleeding disorder or coagulation disorder or
thrombocytopenia or pro-thrombotic disorder.

14. The patient has a history of anaphylaxis or severe allergic reaction to vaccines or
unknown allergens.

15. The patient has a known immediate or delayed hypersensitivity reaction or
idiosyncrasy to drugs chemically related to Lapatinib. These include other
anilinoquinazolines, such as gefitinib (Iressa), erlotinib (Tarceva), or other
chemically related compounds or excipients.

16. The patient is known to be positive for the Human Immunodeficiency Virus (HIV).

17. The patient has (or has had) previous or concomitant malignancies at other sites
except effectively treated:

- Non-melanoma skin cancers or carcinoma in situ of the cervix

- Malignancy that has been in remission for > 2 years and is considered highly
likely to have been cured.

18. The patient has any psychiatric or addictive disorder that may compromise her ability
to give informed consent, or to comply with the trial procedures.

19. The patient has any other condition that in the opinion of the investigator might
jeopardize the patient's safety or ability to comply with the requirements of the

20. The patient is pregnant or lactating.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

The safety of dHER2+AS15 ASCI when administered in combination with Lapatinib measured by dose limiting toxicity.

Outcome Time Frame:

26 weeks

Safety Issue:


Principal Investigator

Michael Morse, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Duke University


United States: Food and Drug Administration

Study ID:




Start Date:

July 2009

Completion Date:

April 2012

Related Keywords:

  • Metastatic Breast Cancer
  • breast cancer
  • HER2
  • Lapatinib
  • dHER2 ASCI
  • overexpressing HER2
  • refractory to trastuzumab
  • Breast Neoplasms



Duke University Medical CenterDurham, North Carolina  27710